Boston Scientific Corporation Enrolls the First Patient in a New Registry to Evaluate the Value of the Vercise™ Deep Brain Stimulation (DBS) System

Share

(April 11, 2014) - Boston Scientific Corporation has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise™ Deep Brain Stimulation (DBS) System in patients with Parkinson's disease. The multi-center, prospective study is expected to enroll up to 300 patients with PD at leading hospitals internationally and will be led by co-principal investigators Prof. Dr. Gunther Deuschl, director of the Department of Neurology, University Hospital, Kiel, Germany, and Prof. Dr. Jan Vesper, Department of Functional Neurosurgery and Stereotaxy at Heinrich-Heine University Hospital in Dusseldorf, Germany. Read more…

Click for a printer friendly version

Back to top